X4 Pharmaceuticals (XFOR) EBITDA (2017 - 2025)

X4 Pharmaceuticals (XFOR) has 9 years of EBITDA data on file, last reported at -$23.7 million in Q4 2025.

• For the quarter ending Q4 2025, EBITDA rose 33.64% year-over-year to -$23.7 million; the trailing twelve-month figure through Dec 2025 stood at -$86.9 million (down 138.68% YoY), and the FY2025 full-year result was -$86.9 million, down 131.98% from the prior year.
• EBITDA for Q4 2025 stood at -$23.7 million, up from -$27.5 million in the prior quarter.
• Across five years, EBITDA topped out at $71.1 million in Q2 2024 and bottomed at -$37.3 million in Q1 2024.
• The 5-year median for EBITDA is -$25.4 million (2022), against an average of -$20.2 million.
• The widest annual swing landed in 2024, when EBITDA surged 375.54%; it then plunged 136.89% in 2025.
• A 5-year view of EBITDA shows it stood at -$29.1 million in 2021, then increased by 11.97% to -$25.6 million in 2022, then increased by 1.48% to -$25.2 million in 2023, then plunged by 41.73% to -$35.7 million in 2024, then jumped by 33.64% to -$23.7 million in 2025.
• The last three EBITDA figures came in at -$23.7 million (Q4 2025), -$27.5 million (Q3 2025), and -$26.2 million (Q2 2025), per Business Quant data.

Peer Comparison